“…(a) The noncompetitive antagonists [3H]chlorpromazine and [aH]triphenylmethylphosphonium photolabel residues in M2 (Giraudat, Dennis, Heidmann, Chang, and Changeux, 1986;Hucho, Oberthiir, and Lottspeich, 1986;Oberthtir, Muhn, Baumann, Lottspeich, Wittman-Liebold, and Hucho, 1986;Giraudat, Dennis, Heidmann, Haumont, Lederer, and Changeux, 1987;Giraudat, Galzi, Revah, Changeux, Haumont, and Lederer, 1989;Revah, Galzi, Giraudat, Haumont, Lederer, and Changeux, 1990); (b) mutations in M2 affect single-channel conductance and ion selectivity (Imoto, Methfessel, Sakmann, Mishina, Mori, Konno, Fukuda, Kurasaki, Bujo, Fujita, and Numa, 1986;Imoto, Busch, Sakmann, Mishina, Konno, Nakai, Bujo, Mori, Fukuda, and Numa, 1988;Leonard, Labarca, Charnet, Davidson, and Lester, 1988;Charnet, Labarca, Leonard, Vogelaar, Czyzyk, Gouin, Davidson, and Lester, 1990;Imoto, Konno, Nakai, Wang, Mishina, and Numa, 1991;Konno, Busch, von Kitzing, Imoto, Wang, Nakai, Mishina, Numa, and Sakmann, 1991;Villarroel, Herlitze, Koenen, and Sakmann, 1991;Cohen, Labarca, Czyzyk, Davidson, and Lester, 1992); and (c) mutations in M2 affect block of the nAChR by QX-222 (Leonard et al, 1988;Charnet et al, 1990). M1 may also form part of the pore lining (DiPaola, Kao, and Karlin, 1990).…”